Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia.

活化受体NKP46（CD335）在人自然杀伤细胞和T细胞肿瘤中的表达情况

Freud AG,Zhao S,Wei S,Gitana GM,Molina-Kirsch HF,Atwater SK,Natkunam Y

阅读：872 American Journal of Clinical Pathology； 2013 December; 140 (6)

Abstract

To evaluate the expression of CD335 (NKp46), an activation receptor that is selectively expressed on natural killer (NK) cells.
We assessed CD335's potential utility as a diagnostic marker in 657 cases by flow cytometry and 410 cases by immunohistochemistry.
We observed that CD335 was highly specific for NK cells in nonneoplastic tissues. Moreover, 61 (90%) of 68 of NK cell neoplasms demonstrated CD335 expression, whereas B-cell, myelomonocytic, and plasma cell neoplasms lacked expression. Notably, 16 (20%) of 82 mature T-cell neoplasms, particularly T-cell large granular lymphocytic leukemia, mycosis fungoides, and ALK+ anaplastic large cell lymphoma, aberrantly expressed CD335.
Collectively, these data support the diagnostic utility of CD335 in evaluating hematopoietic malignancies and suggest that CD335 could be a useful target for selective immunotherapy in patients with mature NK and T-cell neoplasms.

摘要

目的：为了评价选择性表达于自然杀伤（NK）细胞的活化受体CD335（NKP46）的表达情况。
方法：我们通过657例流式细胞学和410例免疫组化诊断法评估CD335作为诊断标记物的潜在作用。
结果：我们观察到CD335是在非肿瘤组织的NK细胞中具有高度特异性。此外，在68例NK细胞肿瘤中有61例（90％）表达CD335，而B细胞肿瘤、骨髓单核细胞肿瘤、浆细胞瘤则缺乏表达。值得注意的是，在82例成熟T细胞肿瘤中有16例（20％），特别是T细胞大颗粒淋巴细胞白血病、蕈样霉菌病以及ALK阳性间变性大细胞淋巴瘤，则异常表达CD335。
结论：总的来说，这些数据支持了CD335在造血系统恶性肿瘤中的诊断作用，并表明CD335可能是成熟NK细胞和T细胞肿瘤患者选择性免疫治疗的有用靶点。

full text

我要评论

共0条评论

本文译者

小谷
译文：51 篇